本次范围审查旨在评估立体定向全身放射治疗 (SBRT) 增强作为近距离放射治疗 (BCT) 治疗宫颈癌的潜在替代方案的证据。在多个数据库中进行了全面的文献检索。研究纳入了对禁忌 BCT 或拒绝 BCT 的宫颈癌患者进行 SBRT 加强治疗的研究。该综述检查了 SBRT 的有效性和安全性。纳入了 16 项研究，包括前瞻性 (n = 4) 和回顾性队列研究 (n = 8)，以及 I 期和 II 期试验 (n = 4)。最常见的 SBRT 加强剂量为 25 格雷 (Gy)/5 次（范围为 18 至 40Gy/3-5 次）。 1年、3年和5年的局部控制率分别为86%至100%、78-92%和81-92%。 1 年、3 年和 5 年总生存率 (OS) 分别为 49% 至 95%、50-77% 和 50-69%。两项研究报告 SBRT 加强后三个月的病理完全缓解率分别为 93% 和 94%。大多数研究报告晚期 3 级或以上泌尿生殖系统 (0-14%) 和胃肠道 (0-26%) 毒性的发生率较低。直肠阴道瘘的总体发生率范围为 0% 至 13%。本次范围审查表明，SBRT 加强治疗对于无法接受 BCT 的特定宫颈癌患者来说是一种有希望的替代方案。结果表明局部控制程度高且毒性特征可接受。然而，需要进一步研究来定义最佳 SBRT 加强参数、确定患者选择标准并解决有关长期结果和成本效益的知识差距。版权所有 © 2024 Elsevier B.V。保留所有权利。

This scoping review aims to evaluate the evidence for stereotactic body radiotherapy (SBRT) boost as a potential alternative for brachytherapy (BCT) in treating cervical cancer.A comprehensive literature search was conducted across multiple databases. Studies investigating SBRT boost in cervical cancer patients who were either contraindicated for or refused BCT were included. The review examined SBRT efficacy and safety.Sixteen studies were included, encompassing prospective (n = 4) and retrospective cohort studies (n = 8), as well as phase I and II trials (n = 4). The most common SBRT boost dose was 25 Gray(Gy)/5 fractions (ranging from 18 to 40 Gy/3-5 fractions). Local control rates at 1-year, 3-year, and 5-year ranged from 86 % to 100 %, 78-92 %, and 81-92 %, respectively. Overall survival (OS) rates at 1-year, 3-year, and 5-year rates ranged from 49 % to 95 %, 50-77 %, and 50-69 %, respectively. Two studies reported a pathological complete response rate of 93 % and 94 % three months after the SBRT boost. Most studies reported low rates of late grade 3 or higher genitourinary (0-14 %) and gastrointestinal (0-26 %) toxicities. The overall incidence of rectovaginal fistulas ranged from 0 % to 13 %.This scoping review suggests SBRT boost as a promising alternative to selected cervical cancer patients who cannot receive BCT. The results indicate a high local control with acceptable toxicity profiles. However, further research is needed to define optimal SBRT boost parameters, identify patient selection criteria, and address knowledge gaps regarding long-term outcomes and cost-effectiveness.Copyright © 2024 Elsevier B.V. All rights reserved.